MTCR - Metacrine completes enrollment in mid-stage NASH trial

Metacrine (MTCR) has completed enrollment for its Phase 2a trial evaluating MET409 in combination with empagliflozin (Jardiance), a sodium-glucose cotransport-2 ((SGLT2)) inhibitor, in patients with type 2 diabetes and non-alcoholic steatohepatitis ((NASH)).The company plans to report topline data from the study in the fourth quarter of 2021.The Phase 2a study is a 12-week, randomized, placebo-controlled, multi-center trial to evaluate the safety, tolerability and pharmacological activity, as measured by reductions in liver fat content with magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF), of MET409 (50 mg) and empagliflozin (10 mg) vs individual monotherapy components and placebo.Shares up marginally during premarket trading.

For further details see:

Metacrine completes enrollment in mid-stage NASH trial